Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (481-490 of 703) with videos related to

Pageof 71
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1BMatteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorKevin B Kim, Richard Kefford, Anna C Pavlick, et al.
Human Molecular Genetics|January 7, 2021
Germline variants are associated with increased primary melanoma tumor thickness at diagnosisErnest Mangantig, Stuart MacGregor, Mark M Iles, et al.
JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Journal for Immunotherapy of Cancer|January 31, 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case seriesCatriona Harvey, Kazi J Nahar, Janet McKeown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2019
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint BlockadeImran G House, Peter Savas, Junyun Lai, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 studyDirk Schadendorf, James Larkin, Jedd Wolchok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced MelanomaAntoni Ribas, Mohammed M Milhem, Christopher J Hoimes, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2022
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomesJoanna Lee, Tasnia Ahmed, Andrea Maurichi, et al.
Nature Medicine|January 8, 2025
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trialReinhard Dummer, Caroline Robert, Richard A Scolyer, et al.
Pageof 71

Showing results (481-490 of 703) with videos related to

Sort By:
Pageof 71
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1BMatteo S Carlino, Alexander M Menzies, Victoria Atkinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitorKevin B Kim, Richard Kefford, Anna C Pavlick, et al.
Human Molecular Genetics|January 7, 2021
Germline variants are associated with increased primary melanoma tumor thickness at diagnosisErnest Mangantig, Stuart MacGregor, Mark M Iles, et al.
JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Journal for Immunotherapy of Cancer|January 31, 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case seriesCatriona Harvey, Kazi J Nahar, Janet McKeown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2019
Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint BlockadeImran G House, Peter Savas, Junyun Lai, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 studyDirk Schadendorf, James Larkin, Jedd Wolchok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 25, 2025
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naive Advanced MelanomaAntoni Ribas, Mohammed M Milhem, Christopher J Hoimes, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2022
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomesJoanna Lee, Tasnia Ahmed, Andrea Maurichi, et al.
Nature Medicine|January 8, 2025
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trialReinhard Dummer, Caroline Robert, Richard A Scolyer, et al.
Pageof 71